{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T20:48:27Z","timestamp":1779396507652,"version":"3.53.1"},"reference-count":27,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2015,9,20]],"date-time":"2015-09-20T00:00:00Z","timestamp":1442707200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P01 CA108964"],"award-info":[{"award-number":["P01 CA108964"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U01 CA37429"],"award-info":[{"award-number":["U01 CA37429"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"published-print":{"date-parts":[[2016,3]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      To evaluate the associations of non\u2010steroidal anti\u2010inflammatory drug (\n                      <jats:styled-content style=\"fixed-case\">NSAID<\/jats:styled-content>\n                      ) use with risk of erectile dysfunction (\n                      <jats:styled-content style=\"fixed-case\">ED<\/jats:styled-content>\n                      ), considering the indications for\n                      <jats:styled-content style=\"fixed-case\">NSAID<\/jats:styled-content>\n                      use.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>\n                      We analysed data from 4 726 men in the placebo arm of the Prostate Cancer Prevention Trial (\n                      <jats:styled-content style=\"fixed-case\">PCPT<\/jats:styled-content>\n                      ) without evidence of\n                      <jats:styled-content style=\"fixed-case\">ED<\/jats:styled-content>\n                      at baseline. Incident\n                      <jats:styled-content style=\"fixed-case\">ED<\/jats:styled-content>\n                      was defined as mild\/moderate (decrease in normal function) or severe (absence of function). Proportional hazards models were used to estimate the covariate\u2010adjusted associations of\n                      <jats:styled-content style=\"fixed-case\">NSAID<\/jats:styled-content>\n                      \u2010related medical conditions and time\u2010dependent\n                      <jats:styled-content style=\"fixed-case\">NSAID<\/jats:styled-content>\n                      use with\n                      <jats:styled-content style=\"fixed-case\">ED<\/jats:styled-content>\n                      risk.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Arthritis (hazard ratio [\n                      <jats:styled-content style=\"fixed-case\">HR<\/jats:styled-content>\n                      ] 1.56), chronic musculoskeletal pain (\n                      <jats:styled-content style=\"fixed-case\">HR<\/jats:styled-content>\n                      1.35), general musculoskeletal complaints (\n                      <jats:styled-content style=\"fixed-case\">HR<\/jats:styled-content>\n                      1.36), headaches (\n                      <jats:styled-content style=\"fixed-case\">HR<\/jats:styled-content>\n                      1.44), sciatica (\n                      <jats:styled-content style=\"fixed-case\">HR<\/jats:styled-content>\n                      1.50) and atherosclerotic disease (\n                      <jats:styled-content style=\"fixed-case\">HR<\/jats:styled-content>\n                      1.60) were all significantly associated with an increased risk of mild\/moderate\n                      <jats:styled-content style=\"fixed-case\">ED<\/jats:styled-content>\n                      , while only general musculoskeletal complaints (\n                      <jats:styled-content style=\"fixed-case\">HR<\/jats:styled-content>\n                      1.22), headaches (\n                      <jats:styled-content style=\"fixed-case\">HR<\/jats:styled-content>\n                      1.47) and atherosclerotic disease (\n                      <jats:styled-content style=\"fixed-case\">HR<\/jats:styled-content>\n                      1.60) were associated with an increased risk of severe\n                      <jats:styled-content style=\"fixed-case\">ED<\/jats:styled-content>\n                      . Non\u2010aspirin\n                      <jats:styled-content style=\"fixed-case\">NSAID<\/jats:styled-content>\n                      use was associated with an increased risk of mild\/moderate\n                      <jats:styled-content style=\"fixed-case\">ED<\/jats:styled-content>\n                      (\n                      <jats:styled-content style=\"fixed-case\">HR<\/jats:styled-content>\n                      1.16;\n                      <jats:italic>P<\/jats:italic>\n                      = 0.02) and aspirin use was associated with an increased risk of severe\n                      <jats:styled-content style=\"fixed-case\">ED<\/jats:styled-content>\n                      (\n                      <jats:styled-content style=\"fixed-case\">HR<\/jats:styled-content>\n                      1.16;\n                      <jats:italic>P<\/jats:italic>\n                      = 0.03, respectively). The associations of\n                      <jats:styled-content style=\"fixed-case\">NSAID<\/jats:styled-content>\n                      use with\n                      <jats:styled-content style=\"fixed-case\">ED<\/jats:styled-content>\n                      risk were attenuated after controlling for indications for\n                      <jats:styled-content style=\"fixed-case\">NSAID<\/jats:styled-content>\n                      use.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      The modest associations of\n                      <jats:styled-content style=\"fixed-case\">NSAID<\/jats:styled-content>\n                      use with\n                      <jats:styled-content style=\"fixed-case\">ED<\/jats:styled-content>\n                      risk in the present cohort were probably attributable to confounding indications for\n                      <jats:styled-content style=\"fixed-case\">NSAID<\/jats:styled-content>\n                      use.\n                      <jats:styled-content style=\"fixed-case\">NSAID<\/jats:styled-content>\n                      use was not associated with\n                      <jats:styled-content style=\"fixed-case\">ED<\/jats:styled-content>\n                      risk.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/bju.13264","type":"journal-article","created":{"date-parts":[[2015,8,25]],"date-time":"2015-08-25T11:51:52Z","timestamp":1440503512000},"page":"500-506","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Non\u2010steroidal anti\u2010inflammatory drug (\n                    <scp>NSAID<\/scp>\n                    ) use is not associated with erectile dysfunction risk: results from the Prostate Cancer Prevention Trial"],"prefix":"10.1111","volume":"117","author":[{"given":"Darshan P.","family":"Patel","sequence":"first","affiliation":[{"name":"Division of Urology University of Utah Salt Lake City UT USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeannette M.","family":"Schenk","sequence":"additional","affiliation":[{"name":"Cancer Prevention Program Fred Hutchinson Cancer Research Center Seattle WA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Darke","sequence":"additional","affiliation":[{"name":"SWOG Statistical Center Fred Hutchinson Cancer Research Center Seattle WA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy B.","family":"Myers","sequence":"additional","affiliation":[{"name":"Division of Urology University of Utah Salt Lake City UT USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William O.","family":"Brant","sequence":"additional","affiliation":[{"name":"Division of Urology University of Utah Salt Lake City UT USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M.","family":"Hotaling","sequence":"additional","affiliation":[{"name":"Division of Urology University of Utah Salt Lake City UT USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,9,20]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-139-3-200308050-00005"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2006.06.010"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.281.6.537"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)67900-1"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2007.01.057"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2012.06.015"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1743-6109.2012.02816.x"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF03347500"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1743-6109.2010.01762.x"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijir.3901519"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehl341"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2007.08.004"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2012.04.001"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200890"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2013.10.013"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/BRS.0b013e3182830482"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2012.12.107"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1186\/1129-2377-14-46"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar3748"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.287.3.337"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2010.11.092"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)01000-1"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030660"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.294.23.2996"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djm023"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.1999.tb01603.x"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1097\/00045391-200205000-00005"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbju.13264","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bju.13264","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:19:10Z","timestamp":1761743950000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/bju.13264"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,20]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["10.1111\/bju.13264"],"URL":"https:\/\/doi.org\/10.1111\/bju.13264","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"value":"1464-4096","type":"print"},{"value":"1464-410X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,20]]},"assertion":[{"value":"2015-09-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}